Precision Oncology is still of relevance

Dr. Innocenti is an Associate Professor with Permanent Tenure in the Division of Pharmacotherapy and Experimental Therapeutics of the UNC Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill. He is the Associate Director of the Center for Pharmacogenomics and Individualized Therapy.
Dr. Innocenti obtained his MD from the University of Pisa, Pisa, Italy, followed by residencies in Clinical Pharmacology and Oncology. He holds a PhD in Pharmacology, Toxicology, and Chemotherapy from the same institution.
Dr. Innocenti serves as the Chair of the Gastrointestinal Solid Tumor Correlative Science Group of the Alliance of Clinical Trials in Oncology.
He has published more than 140 peer-reviewed publications and book chapters. Dr. Innocenti sits on the editorial board of Clinical Pharmacology and Therapeutics, Pharmacogenetics and Genomics, and Current Drug Metabolism. He is the Associate Editor of Pharmacogenomics.
One of Dr. Innocenti's exemplary achievements is the elucidation of the genetic basis of severe neutropenia in cancer patients treated with irinotecan, which led to a change in the drug label. Dr. Innocenti is a co-inventor of the UGT1A1 genetic test.
Dr. Innocenti's NIH-funded research program is currently focused on the discovery of genomic determinants of efficacy and toxicity of cancer treatments.